Journal articleBMJ Open · June 17, 2026
INTRODUCTION: Cannabis use is common in the USA and is associated with adverse outcomes across many domains, including sleep difficulties. Targeting insomnia with an evidence-based treatment could improve sleep and reduce frequent cannabis use. This random ...
Full textLink to itemCite
Journal articleJMIR AI · June 8, 2026
BACKGROUND: Large language models (LLMs) and, more recently, large reasoning models (LRMs) have rapidly garnered significant interest for application in psychiatry and behavioral health. However, recent studies have identified significant shortcomings and ...
Full textLink to itemCite
Journal articleBehav Sleep Med · June 5, 2026
OBJECTIVES: Cognitive behavioral therapy for insomnia (CBT-I) is widely recommended, but access remains limited, particularly among rural adults. Medications to treat insomnia, including zolpidem and trazodone, are widely used but can have significant side ...
Full textLink to itemCite
Journal articleJ Affect Disord · June 1, 2026
INTRODUCTION: Treatment-refractory obsessive-compulsive disorder (trOCD) is a complex network disorder that may require personalized treatment strategies due to disease heterogeneity. A multi-site, multi-stage, double-blinded, randomized crossover clinical ...
Full textLink to itemCite
Journal articleSleep Med · June 2026
OBJECTIVE: Cognitive disengagement syndrome (CDS) is an attentional phenotype characterized by excessive daydreaming and hypoactivity that is distinct from attention-deficit/hyperactivity disorder (ADHD). Emerging research finds poorer sleep functioning to ...
Full textLink to itemCite
Journal articlePsychiatry Res · May 12, 2026
Anhedonia is a highly prevalent core pathognomonic symptom of a major depressive episode seen in major depressive disorder (MDD) and bipolar disorder. The symptom is associated with functional impairment, increased suicidality, psychiatric and somatic como ...
Full textLink to itemCite
Journal articleSci Rep · April 22, 2026
Mobile electroencephalography (EEG) may offer a scalable, cost-effective way to capture neural signatures of Parkinson’s disease (PD) in low-resource settings. In a cross-sectional cohort of 44 individuals with PD in Lima, Peru evaluated “off-medication”, ...
Full textLink to itemCite
Journal articleNeuromodulation · April 2026
OBJECTIVES: Deep brain stimulation (DBS) is increasingly being used to treat a variety of neuropsychiatric conditions, many of which exhibit idiosyncratic symptom presentations and neural correlates across individuals. Thus, we have used inpatient stereoel ...
Full textLink to itemCite
Journal articleSleep Med Rev · April 2026
A variety of pharmacologic treatments are approved for insomnia, encompassing a range of mechanisms of action, including some treatments with published data in models of acute insomnia. However, most studies are conducted in individuals with chronic insomn ...
Full textLink to itemCite
Journal articleCurr Biol · March 23, 2026
The orbitofrontal cortex (OFC) is a nexus for decision-making computations,1 emotion,2 and pain processing,3 with dissociable roles for its subfields: medial and anterior OFC are thought to represent economic value,4,5,6 whereas lateral OFC receives predom ...
Full textLink to itemCite
Journal articleTrials · January 13, 2026
BACKGROUND: Eligibility criteria are a critical component of a well-designed clinical trial, enhancing trial safety and internal validity. Yet, data suggest that exclusion rates based on these criteria often vary by participant race/ethnicity. METHOD: This ...
Full textLink to itemCite
Journal articlePsychiatry Res · January 2026
BACKGROUND AND METHODS: The authors sought to evaluate the performance of common large language models (LLMs) in psychiatric diagnosis, and the impact of integrating expert-derived reasoning on their performance. Clinical case vignettes and associated diag ...
Full textLink to itemCite
Journal articleBrain Stimul · 2026
BACKGROUND: Transcranial low-intensity focused ultrasound (LIFU) is an emerging tool for noninvasive neuromodulation, with potential therapeutic applications across a range of neuropsychiatric disorders. As the field advances toward clinical translation, i ...
Full textLink to itemCite
Journal articleImaging Neurosci (Camb) · 2026
Non-invasive transcranial ultrasound stimulation (TUS) enables deep brain therapeutic exploration at unprecedented scale. However, its optimal use is limited by the uncertainty surrounding ultrasound sensitivity across brain regions and cell types. This un ...
Full textLink to itemCite
Journal articleJMIR Ment Health · December 4, 2025
BACKGROUND: Cognitive behavioral therapy (CBT) is recommended as the first-line treatment for insomnia; however, few patients have access to it. A new class of Food and Drug Administration (FDA)-regulated digital CBT treatments has the potential to address ...
Full textLink to itemCite
Journal articleBiol Psychiatry Cogn Neurosci Neuroimaging · November 2025
BACKGROUND: Anhedonia, the loss of pleasure, is prevalent and impairing. Parsing its computational basis promises to explain its transdiagnostic character. One manifestation of anhedonia, reward insensitivity, may be linked to limited memory. Furthermore, ...
Full textLink to itemCite
Journal articleAlzheimers Dement · November 2025
INTRODUCTION: Sleep disturbances are common in older people with cognitive impairment, potentially contributing to negative outcomes. A core outcome set (COS) is required to reduce heterogeneity in clinical trials and promote the development of high-qualit ...
Full textLink to itemCite
Journal articleTransl Psychiatry · October 31, 2025
Deep brain stimulation has been used to treat severe, refractory obsessive-compulsive disorder (OCD) with variable outcomes across multiple anatomical targets. To overcome these limitations, we developed an invasive brain mapping paradigm in which electrod ...
Full textLink to itemCite
Journal articleAlzheimers Dement · October 2025
INTRODUCTION: Distinguishing behavioral variant frontotemporal dementia (bvFTD) from primary psychiatric disorders (PPDs) remains challenging due to overlapping clinical presentation. Neurofilament light chain (NfL) is a biomarker of neuronal damage that i ...
Full textLink to itemCite
Journal articleJ Mood Anxiety Disord · September 2025
BACKGROUND: Anhedonia remains a difficult-to-treat symptom and has been associated with poor clinical course transdiagnostically. Here, we applied machine learning models to individualized neural patches derived from fMRI data during the Monetary Incentive ...
Full textLink to itemCite
Journal articleJ Clin Psychopharmacol · September 2025
BACKGROUND: Anhedonia is a core symptom of major depressive disorder (MDD) that may result from aberrant lateral habenula hyperactivity. Targeting G-protein coupled receptor 139 (GPR139) may improve anhedonia by modulating lateral habenula activity. NBI-10 ...
Full textLink to itemCite
Journal articleJAMA Psychiatry · August 13, 2025
IMPORTANCE: Existing pharmacological treatments for insomnia have significant limitations. OBJECTIVE: To assess the effective dose range, safety, and tolerability of the novel selective orexin-2 receptor antagonist seltorexant in insomnia disorder. DESIGN, ...
Full textLink to itemCite
Journal articleNeuropsychopharmacology · August 2025
In our prior study involving a transdiagnostic sample of individuals with anhedonia, we showed that an 8-week administration of a selective κ-opioid receptor (KOR) antagonist enhanced fMRI ventral striatal activation during reward anticipation in the Monet ...
Full textLink to itemCite
Journal articleJ Clin Psychiatry · June 2, 2025
Objective: This review of the relationship between idiopathic hypersomnia and psychiatric disorders describes considerations in recognizing and managing complaints of excessive daytime sleepiness (EDS) in patients in psychiatric clinical practice. Data Sou ...
Full textLink to itemCite
Journal articleJ Med Internet Res · May 20, 2025
BACKGROUND: Large language models (LLMs), such as OpenAI's GPT-3.5, GPT-4, and GPT-4o, have garnered early and significant enthusiasm for their potential applications within mental health, ranging from documentation support to chat-bot therapy. Understandi ...
Full textLink to itemCite
Journal articleJ Neurosurg Case Lessons · April 14, 2025
BACKGROUND: The authors present a case of a young patient who presented with depression symptoms and epilepsy. She was found to have a low-grade glioneuronal tumor located in the septal region, a critical limbic area involved in neuropsychiatric disorders. ...
Full textLink to itemCite
Journal articleSleep Breath · April 14, 2025
INTRODUCTION: Most pharmacologic treatments with clinical data for insomnia symptoms are controlled substances. An exception is doxepin, an antihistamine that has shown efficacy for the treatment of difficulties with sleep maintenance. This analysis assess ...
Full textLink to itemCite
Journal articleNeuropsychopharmacol Rep · March 2025
AIM: Individuals with insomnia frequently have comorbid depression or anxiety. This study sought to provide a preliminary indication of the effects of lemborexant (LEM) in subjects treated for mild depression/anxiety symptoms. METHODS: E2006-G000-303 (NCT0 ...
Full textLink to itemCite
Journal articleBrain Behav Immun · March 2025
Despite tremendous advancements in neuroscience, there has been limited impact on patient care. Current psychiatric treatments are largely non-specific, and drug development is hindered by outdated, overinclusive diagnostic categories and a "one-size-fits- ...
Full textLink to itemCite
Journal articleJ Am Acad Child Adolesc Psychiatry · February 2025
OBJECTIVE: Few studies have characterized the nature of sleep problems among adolescents with attention-deficit/hyperactivity disorder (ADHD) using polysomnography (PSG). Additionally, although adolescents with ADHD and adolescents with sleep disturbances ...
Full textLink to itemCite
Journal articleJ Sleep Res · February 2025
Sleep architecture encodes relevant information on the structure of sleep and has been used to assess hyperarousal in insomnia. This study investigated whether polysomnography-derived sleep architecture displays signs of hyperarousal in individuals with in ...
Full textLink to itemCite
Journal articleBehav Sleep Med · 2025
OBJECTIVE: Using data from a nationwide recruitment campaign for an RCT evaluating digital cognitive behavioral therapy for prenatal insomnia, we tested whether a recruitment message that identified a racial/ethnic disparity in sleep quality (sleep dispari ...
Full textLink to itemCite
Journal articleFront Hum Neurosci · 2025
Deep brain stimulation (DBS) is well suited to target disorders with network dysregulation, as is the case in many neuropsychiatric diseases. While DBS is a well-established therapy for Parkinson's disease, essential tremor, dystonia, and medically refract ...
Full textLink to itemCite
Journal articleHum Brain Mapp · December 15, 2024
Deep brain stimulation (DBS) of the anterior limb of the internal capsule (ALIC) is a circuit-based treatment for severe, refractory obsessive-compulsive disorder (OCD). The therapeutic effects of DBS are hypothesized to be mediated by direct modulation of ...
Full textLink to itemCite
Journal articleAlzheimer's & dementia : the journal of the Alzheimer's Association · December 1, 2024
Those with neurodegenerative conditions have an increased risk of developing delirium and there is some evidence that delirium may be a risk factor for neurodegenerative disorders. Similar to the interactions between sleep and neurodegenerative conditions, ...
Full textCite
Journal articleSleep · November 8, 2024
STUDY OBJECTIVES: Post hoc analysis to evaluate the effect of daridorexant on sleep architecture in people with insomnia, focusing on features associated with hyperarousal. METHODS: We studied sleep architecture in adults with chronic insomnia disorder fro ...
Full textLink to itemCite
Journal articleNeurosurgery · October 1, 2024
BACKGROUND AND OBJECTIVES: Treatment-resistant depression is a leading cause of disability. Our center's trial for neurosurgical intervention for treatment-resistant depression involves a staged workup for implantation of a personalized, closed-loop neurom ...
Full textLink to itemCite
Journal articleJ Psychopharmacol · September 2024
BACKGROUND: There are limited data regarding gamma-aminobutyric acid (GABA) allosteric modulator sleep-aid medications in persons with depression, insomnia, and suicidal ideation (SI). AIMS: This secondary analysis examined the relationship of age to insom ...
Full textLink to itemCite
Journal articleJ Sleep Res · August 2024
Several professional societies have provided recommendations for prescribing medications for insomnia. None has provided an integrative analysis that concurrently quantifies safety and efficacy (e.g., risk-benefit ratios). This represents an important gap ...
Full textLink to itemCite
Journal articleNeurology · April 23, 2024
BACKGROUND AND OBJECTIVES: Insomnia affects about one-third of patients with traumatic brain injury and is associated with worsened outcomes after injury. We hypothesized that higher levels of plasma neuroinflammation biomarkers at the time of TBI would be ...
Full textLink to itemCite
Journal articleSleep Med · February 2024
OBJECTIVE/BACKGROUND: Discrepancies between sleep diaries and actigraphy occur among individuals with insomnia. Cognitive behavioural therapy for insomnia (CBT-I) improves insomnia but the impact on discrepancy is unclear. This study examined CBT-I's effec ...
Full textLink to itemCite
Journal articleNeuropsychopharmacology · January 2024
Despite increasing prevalence and huge personal and societal burden, psychiatric diseases still lack treatments which can control symptoms for a large fraction of patients. Increasing insight into the neurobiology underlying these diseases has demonstrated ...
Full textLink to itemCite
Journal articleFront Hum Neurosci · 2024
The Deep Brain Stimulation (DBS) Think Tank XI was held on August 9-11, 2023 in Gainesville, Florida with the theme of "Pushing the Forefront of Neuromodulation". The keynote speaker was Dr. Nico Dosenbach from Washington University in St. Louis, Missouri. ...
Full textLink to itemCite
Journal articleBehav Sleep Med · 2024
OBJECTIVES: The main objectives of the current paper were to examine the feasibility, acceptability, and adherence of a remotely delivered intervention consisting of mindfulness-based stress reduction plus prenatal sleep classes (MBSR+PS) compared with tre ...
Full textLink to itemCite
Journal articlePsychiatry Res · December 2023
The REST-IT study found the addition of zolpidem-controlled release (CR) provided a significant reduction in observer-rated measurement of suicidal ideation (the Columbia Suicide Severity Rating Scale) in 103 depressed outpatients with insomnia and suicida ...
Full textLink to itemCite
Journal articleJ Sleep Res · December 2023
This article reviews the history of insomnia pharmacotherapy, documenting the evolution that has occurred over time in the increasing availability of medications with novel mechanisms of action that more specifically target the neural systems that modulate ...
Full textLink to itemCite
Journal articleJAMA Netw Open · December 1, 2023
IMPORTANCE: Daytime functional impairments are the primary reasons for patients with insomnia to seek treatment, yet little is known about what the optimal treatment is for improving daytime functions and how best to proceed with treatment for patients who ...
Full textLink to itemCite
Journal articleJ Neurosci · November 29, 2023
Sleep is a highly stereotyped phenomenon, requiring robust spatiotemporal coordination of neural activity. Understanding how the brain coordinates neural activity with sleep onset can provide insights into the physiological functions subserved by sleep and ...
Full textLink to itemCite
Journal articleJ Neurotrauma · November 2023
We previously described five trajectories of insomnia (each defined by a distinct pattern of insomnia severity over 12 months following traumatic brain injury [TBI]). Our objective in the present study was to estimate the association between insomnia traje ...
Full textLink to itemCite
Journal articleJ Affect Disord · October 15, 2023
BACKGROUND: Growing evidence indicates that anhedonia is a multifaceted construct. This study examined the possibility of identifying subgroups of people with anhedonia using multiple reward-related measures to provide greater understanding the Research Do ...
Full textLink to itemCite
Journal articleJ Vis Exp · July 7, 2023
Deep brain stimulation involves the administration of electrical stimulation to targeted brain regions for therapeutic benefit. In the context of major depressive disorder (MDD), most studies to date have administered continuous or open-loop stimulation wi ...
Full textLink to itemCite
Journal articleInt Forum Allergy Rhinol · July 2023
BACKGROUND: Evaluation and interpretation of the literature on obstructive sleep apnea (OSA) allows for consolidation and determination of the key factors important for clinical management of the adult OSA patient. Toward this goal, an international collab ...
Full textLink to itemCite
Journal articleJ Clin Sleep Med · June 1, 2023
STUDY OBJECTIVES: Several studies have shown that patients with short sleep duration show a poor response to cognitive behavioral therapy for insomnia (CBT-I), but such studies have not included patients with comorbid conditions. The current study was cond ...
Full textLink to itemCite
Journal articleJ Clin Med · April 24, 2023
A scientific advisory panel of seven U.S. and Canadian sleep experts performed a clinical appraisal by comparing general medical opinion, assessed via a survey of practicing clinicians, regarding insomnia treatment, with the available scientific evidence. ...
Full textLink to itemCite
Journal articleJ Clin Med · April 18, 2023
Trazodone is one of the most commonly used prescription medications for insomnia; however, some recent clinical guidelines do not recommend its use for treating insomnia. This clinical appraisal critically reviews the scientific literature on trazodone as ...
Full textLink to itemCite
Journal articleJ Clin Med · March 25, 2023
Determining the most effective insomnia medication for patients may require therapeutic trials of different medications. In addition, medication side effects, interactions with co-administered medications, and declining therapeutic efficacy can necessitate ...
Full textLink to itemCite
Journal articleJ Clin Med · March 25, 2023
While both patients and physicians consider sleep to be important, sleep health may not receive appropriate consideration during patient visits with health care professionals (HCPs). We completed the first large-scale survey of people with trouble sleeping ...
Full textLink to itemCite
Journal articleJ Clin Med · March 2, 2023
Insomnia is a significant, highly prevalent, persistent public health problem but often remains undiagnosed and untreated. Current treatment practices are not always evidence-based. When insomnia is comorbid with anxiety or depression, treatment often targ ...
Full textLink to itemCite
Journal articleJ Clin Med · February 17, 2023
While evidence supports the benefits of medications for the treatment of chronic insomnia, there is ongoing debate regarding their appropriate duration of use. A panel of sleep experts conducted a clinical appraisal regarding the use of insomnia medication ...
Full textLink to itemCite
Journal articleJ Clin Psychiatry · January 23, 2023
Objective: The aims of this review were to describe the relationship between obstructive sleep apnea (OSA) and psychiatric disorders and provide an overview of how to recognize/manage OSA in psychiatric practice. Data Sources: A literature search of PubMed ...
Full textLink to itemCite
Journal articleJ Affect Disord · January 15, 2023
BACKGROUND: Major depressive disorder (MDD) is largely managed in primary care, but physicians vary widely in their understanding of symptoms and treatments. This study aims to better understand the evolution of depression from initial diagnosis over a 3-y ...
Full textLink to itemCite
Journal articleJ Affect Disord · January 1, 2023
BACKGROUND: Brexanolone is currently the only treatment specifically approved for postpartum depression (PPD) in the United States, based on the results from one Phase 2 and two Phase 3 double-blind, randomized, controlled trials in the HUMMINGBIRD program ...
Full textLink to itemCite
Journal articleBrain Stimul · 2023
BACKGROUND: Humans routinely shift their sleepiness and wakefulness levels in response to emotional factors. The diversity of emotional factors that modulates sleep-wake levels suggests that the ascending arousal network may be intimately linked with netwo ...
Full textLink to itemCite
Journal articleJ Psychiatr Res · November 2022
Given the high rate of depression associated with narcolepsy or obstructive sleep apnea (OSA), this analysis compared effects of solriamfetol treatment of excessive daytime sleepiness (EDS) in participants with/without a history of depression (DHx+/DHx-). ...
Full textLink to itemCite
Journal articleCNS Spectr · April 2022
INTRODUCTION: The dual orexin receptor antagonist lemborexant (LEM) is approved in multiple countries including the United States, Japan, Canada, and Australia for insomnia treatment in adults. In phase 3 study E2006-G000-303 (Study 303; SUNRISE-2; NCT0295 ...
Full textLink to itemCite
Journal articleGlobal Advances in Health and Medicine · March 16, 2022
Background: Poor sleep is common during pregnancy and is associated with increased risk of negative health outcomes. Research indicates that physical discomfort and having an active mind are primary factors for prenatal sleep disturbances. Mindfulness-base ...
Full textCite
Journal articleMol Psychiatry · March 2022
Criteria for treatment-resistant depression (TRD) and partially responsive depression (PRD) as subtypes of major depressive disorder (MDD) are not unequivocally defined. In the present document we used a Delphi-method-based consensus approach to define TRD ...
Full textLink to itemCite
Journal articleTrends Neurosci · March 2022
Sleep is intimately related to memory processes. The established view is that the transformation of experiences into long-term memories is linked to sleep-related CNS function. However, there is increasing evidence that the autonomic nervous system (ANS), ...
Full textLink to itemCite
Journal articleSleep · February 14, 2022
STUDY OBJECTIVES: To evaluate the effects of digital cognitive behavior therapy for insomnia (dCBT-I) delivered during pregnancy on subjective sleep outcomes, depressive symptoms, and anxiety symptoms through 6 months postpartum. METHODS: People up to 28 w ...
Full textLink to itemCite
Journal articleTrials · January 20, 2022
BACKGROUND: Alcohol use disorder (AUD) is a leading preventable cause of morbidity and mortality, but relapse rates are high even with available treatments. Insomnia is a robust predictor of relapse and pilot studies have shown that CBT for insomnia improv ...
Full textLink to itemCite
Journal articleJAMA Netw Open · January 4, 2022
IMPORTANCE: Insomnia is common after traumatic brain injury (TBI) and contributes to morbidity and long-term sequelae. OBJECTIVE: To identify unique trajectories of insomnia in the 12 months after TBI. DESIGN, SETTING, AND PARTICIPANTS: In this prospective ...
Full textLink to itemCite
Journal articleNat Sci Sleep · 2022
PURPOSE: Sleep is vital to cognition, yet underlying mechanisms remain unclear. Although sleep duration and continuity are two well-established contributors, additional factors-including homeostatic sleep drive processes-may also underlie cognition-related ...
Full textLink to itemCite
Journal articleSuicide Life Threat Behav · December 2021
INTRODUCTION: Progress reducing suicide death will require randomized clinical trials (RCTs) specifically targeting suicide risk. Even large RCTs may not stipulate suicide death as the primary outcome, as suicide death is relatively uncommon. Therefore, RC ...
Full textLink to itemCite
Journal articleContemp Clin Trials · October 2021
There are currently no validated pharmacotherapies for posttraumatic stress disorder (PTSD)-related insomnia. The purpose of the National Adaptive Trial for PTSD-Related Insomnia (NAP Study) is to efficiently compare to placebo the effects of three insomni ...
Full textLink to itemCite
Journal articleNat Med · October 2021
Deep brain stimulation is a promising treatment for neuropsychiatric conditions such as major depression. It could be optimized by identifying neural biomarkers that trigger therapy selectively when symptom severity is elevated. We developed an approach th ...
Full textLink to itemCite
Journal articleJ Clin Psychiatry · September 28, 2021
Insomnia, the most prevalent sleep-wake disorder, affects 6% to 10% of adults. It may result in interpersonal and occupational problems and has a deleterious effect on quality of life. Patients may experience difficulty with sleep onset, sleep maintenance, ...
Full textLink to itemCite
Journal articleJ Clin Psychiatry · July 13, 2021
By tailoring the mechanism of action and effects of therapy to the specific nature of each patient's insomnia and other conditions, clinicians can offer personalized care in an attempt to achieve an improved risk-benefit ratio compared to that of a "one-si ...
Full textLink to itemCite
Journal articleExpert Opin Pharmacother · July 2021
INTRODUCTION: Insomnia is a complex sleep disorder that compromises quality of life and affects approximately 10% of the general population. Insomnia, defined as trouble initiating or maintaining sleep associated with impaired daytime function or distress, ...
Full textLink to itemCite
Journal articleJAMA Netw Open · July 1, 2021
IMPORTANCE: Disrupted sleep commonly occurs with progressing neurodegenerative disease. Large, well-characterized neuroimaging studies of cognitively unimpaired adults are warranted to clarify the magnitude and onset of the association between sleep and em ...
Full textLink to itemCite
Journal articleJ Clin Psychiatry · June 29, 2021
Older people often experience insomnia, whether it is difficulty initiating or maintaining sleep. These sleep disturbances have a negative impact on quality of life and functioning. This report offers general considerations as well as specific data related ...
Full textLink to itemCite
Journal articleSleep · April 9, 2021
STUDY OBJECTIVES: To examine the cost-effectiveness and potential net monetary benefit (NMB) of a fully automated digital cognitive behavioral therapy (CBT) intervention for insomnia compared with no insomnia treatment in the United States (US). Similar re ...
Full textLink to itemCite
Journal articleCNS Spectr · April 2021
STUDY OBJECTIVES: Depression is an important cause of disability in the United States (US). The care experience of major depressive disorder (MDD) is highly variable and has only been documented to a limited degree. This study examines the prevalence incid ...
Full textLink to itemCite
Journal articleNat Med · February 2021
Deep brain stimulation is a promising treatment for severe depression, but lack of efficacy in randomized trials raises questions regarding anatomical targeting. We implanted multi-site intracranial electrodes in a severely depressed patient and systematic ...
Full textLink to itemCite
Journal articleClin Neurophysiol · February 2021
OBJECTIVE: To determine the best of commonly used methods for computing the rate of decline in non-rapid eye movement (NREM) sleep EEG delta power overnight (Delta Decline) in terms of vulnerability to missing data and to evaluate whether this rate is slow ...
Full textLink to itemCite
Journal articleCurr Biol · January 11, 2021
Sufficient and efficient sleep is crucial for our health. Natural short sleepers can sleep significantly shorter than the average population without a desire for more sleep and without any obvious negative health consequences. In searching for genetic vari ...
Full textLink to itemCite
Journal articleHum Psychopharmacol · January 2021
OBJECTIVES: Information is lacking regarding how commonly unblinding of treatment assignment occurs in hypnotic randomized clinic trials (RCTs). We now report the "best guesses" of clinical trial participants, versus study coordinators, versus study physic ...
Full textLink to itemCite
Journal articleJ Affect Disord · January 1, 2021
BACKGROUND: Circadian rhythm disturbances have been reported in patients with major depressive disorder (MDD). Among these is an increased phase angle between peak cortisol concentration and dim-light melatonin onset (DLMO). The aim of this study was to ev ...
Full textLink to itemCite
Journal articleFront Hum Neurosci · 2021
Major depressive disorder is a common and disabling disorder with high rates of treatment resistance. Evidence suggests it is characterized by distributed network dysfunction that may be variable across patients, challenging the identification of quantitat ...
Full textLink to itemCite
Journal articleSleep Breath · December 2020
PURPOSE: Pulse oximetry is the current standard for detecting drops in arterial blood oxygen saturation (SpO2) associated with obstructive sleep apnea and hypopnea events in polysomnographic (PSG) testing. However, cellular energy monitoring (CE monitoring ...
Full textLink to itemCite
Journal articleJournal of Patient Reported Outcomes · December 1, 2020
Background: The intense itching associated with atopic dermatitis (AD) often causes patients to experience severe sleep disturbance. Here, we describe the results of a two-phase concept elicitation and cognitive interview study to establish the content val ...
Full textCite
Journal articleJAMA Psychiatry · November 1, 2020
IMPORTANCE: Despite evidence of efficacious psychological and pharmacologic therapies for insomnia, there is little information about what first-line treatment should be and how best to proceed when initial treatment fails. OBJECTIVE: To evaluate the compa ...
Full textLink to itemCite
Journal articleJMIR Mhealth Uhealth · October 1, 2020
BACKGROUND: Adolescence is an important life stage for the development of healthy behaviors, which have a long-lasting impact on health across the lifespan. Sleep undergoes significant changes during adolescence and is linked to physical and psychiatric he ...
Full textLink to itemCite
Journal articleNeuropsychopharmacology · September 2020
Anhedonia remains a major clinical issue for which there is few effective interventions. Untreated or poorly controlled anhedonia has been linked to worse disease course and increased suicidal behavior across disorders. Taking a proof-of-mechanism approach ...
Full textLink to itemCite
Journal articleJ Clin Sleep Med · August 15, 2020
STUDY OBJECTIVES: Sleep disturbance is significantly associated with suicidal ideation. However, the majority of past research has examined the relationship between insomnia and suicidality. The current exploratory study examined the relationship of circad ...
Full textLink to itemCite
Journal article · May 25, 2020
BACKGROUNDAdolescence is an important life stage for the development of healthy behaviors, which have a long-lasting impact on health across the lifespan. Sleep undergoes significant chan ...
Full textCite
Journal articleJAMA Psychiatry · May 1, 2020
IMPORTANCE: Despite the prevalence and adverse consequences of prenatal insomnia, a paucity of research is available regarding interventions to improve insomnia symptoms during pregnancy. OBJECTIVE: To test the efficacy of digital cognitive behavioral ther ...
Full textLink to itemCite
Journal articleNat Med · May 2020
The National Institute of Mental Health (NIMH) 'fast-fail' approach seeks to improve too-often-misleading early-phase drug development methods by incorporating biomarker-based proof-of-mechanism (POM) testing in phase 2a. This first comprehensive applicati ...
Full textLink to itemCite
Journal articleCNS Spectr · April 2020
BACKGROUND: SUSTAIN-2 (NCT02497287) was an open-label, phase III trial evaluating the safety of esketamine (ESK) nasal spray plus a newly initiated oral antidepressant (AD) for up to 1 year in adults with treatment-resistant depression (TRD). ESK is a sche ...
Full textLink to itemCite
Journal articleNeuropsychopharmacology · January 2020
Alterations in sleep are extremely common in patients with neuropsychiatric illness. In addition, sleep disorders such as insomnia, obstructive sleep apnea, rapid eye movement sleep behavior disorder, and circadian rhythm disorders commonly occur at a rate ...
Full textLink to itemCite
Journal articleNeuropsychopharmacology · January 2020
Timing and duration of sleep are controlled by the circadian system, which keeps an ~24-h internal rhythm that entrains to environmental stimuli, and the sleep homeostat, which rises as a function of time awake. There is a normal distribution across the po ...
Full textLink to itemCite
Journal articleJ Neuropsychiatry Clin Neurosci · 2020
OBJECTIVES: Adult patients with epilepsy have an increased prevalence of major depressive disorder (MDD). Intracranial EEG (iEEG) captured during extended inpatient monitoring of patients with treatment-resistant epilepsy offers a particularly promising me ...
Full textLink to itemCite
Journal articleAm J Psychiatry · November 1, 2019
OBJECTIVE: The authors sought to determine whether targeted treatment of insomnia with controlled-release zolpidem (zolpidem-CR) in suicidal adults with insomnia would provide a reduction in suicidal ideation superior to placebo. METHODS: Reducing Suicidal ...
Full textLink to itemCite
Journal articleWorld Psychiatry · October 2019
Insomnia poses significant challenges to public health. It is a common condition associated with marked impairment in function and quality of life, psychiatric and physical morbidity, and accidents. As such, it is important that effective treatment is prov ...
Full textLink to itemCite
Journal articleNeuron · September 25, 2019
Sleep is crucial for our survival, and many diseases are linked to long-term poor sleep quality. Before we can use sleep to enhance our health and performance and alleviate diseases associated with poor sleep, a greater understanding of sleep regulation is ...
Full textLink to itemCite
Journal articleSleep Med Clin · September 2019
Pharmacogenetics is the branch of personalized medicine concerned with the variability in drug response occurring because of heredity. Advances in genetics research, and decreasing costs of gene sequencing, are promoting tremendous growth in pharmacogeneti ...
Full textLink to itemCite
Journal articleJ Psychiatr Res · September 2019
In this paper, we report the rate of previously undiagnosed obstructive sleep apnea (OSA) in a randomized clinical trial (RCT) of suicidal patients with major depressive disorder (MDD). One hundred and twenty-five suicidal adults with MDD were recruited in ...
Full textLink to itemCite
Journal articleJ Psychopharmacol · August 2019
This British Association for Psychopharmacology guideline replaces the original version published in 2010, and contains updated information and recommendations. A consensus meeting was held in London in October 2017 attended by recognised experts and advoc ...
Full textLink to itemCite
Journal articleJ ECT · June 2019
OBJECTIVE: Electroconvulsive therapy (ECT) is the most effective treatment for major depression but also carries risk of cognitive side effects. The ability to predict whether treatment will be effective before initiation of treatment could significantly i ...
Full textLink to itemCite
Journal articleJ Clin Sleep Med · April 15, 2019
STUDY OBJECTIVES: We previously presented results from a randomized controlled trial that examined the effects of antidepressant medication plus cognitive behavioral therapy for insomnia (CBT-I) among patients with major depressive disorder (MDD) and insom ...
Full textLink to itemCite
Journal articleJ Sleep Res · April 2019
In this review, we outline the role of orexin receptor antagonists in disorders of sleep/wake and other potential neuropsychiatric conditions, with a focus on suvorexant, which is currently the only approved agent in this class. The efficacy of suvorexant ...
Full textLink to itemCite
Journal articleChest · February 2019
BACKGROUND: Excessive sleepiness (ES) is a common symptom of OSA, which often persists despite primary OSA therapy. This phase III randomized withdrawal trial evaluated solriamfetol (JZP-110) for the treatment of ES in adults with OSA. METHODS: After 2 wee ...
Full textLink to itemCite
Journal articleSleep Med · January 2019
OBJECTIVE: To assess the evolution of narcolepsy symptoms in first-, second, and third-degree relatives and to compare multiplex and simplex families. METHODS: A total of 4045 family members and 362 narcoleptic individuals were entered in the study; with 3 ...
Full textLink to itemCite
Journal articleJ Alzheimers Dis · 2019
BACKGROUND: Recent studies reveal an association between slow-wave sleep (SWS), amyloid-β aggregation, and cognition. OBJECTIVE: This retrospective study examines whether long-term use of trazodone, an SWS enhancer, is associated with delayed cognitive dec ...
Full textLink to itemCite
Journal articleSleep Med Rev · December 2018
Obesity is prevalent among pregnant women in the United States; 15-20% of obese pregnant women have obstructive sleep apnea. The prevalence of obstructive sleep apnea increases along with body mass index, age and in the presence of other co-morbidities. Un ...
Full textLink to itemCite
Journal articleAm J Obstet Gynecol · December 2018
BACKGROUND: Obesity is prevalent among pregnant women in the United States; obstructive sleep apnea is highly comorbid with obesity and is associated with adverse pregnancy outcomes. Screening for obstructive sleep apnea in pregnant women has remained a ch ...
Full textLink to itemCite
Journal articleAnesth Analg · November 2018
Among obese pregnant women, 15%-20% have obstructive sleep apnea (OSA) and this prevalence increases along with body mass index and in the presence of other comorbidities. Prepregnancy obesity and pregnancy-related weight gain are certainly risk factors fo ...
Full textLink to itemCite
Journal articleBiological Rhythm Research · September 3, 2018
The timing of sleep and wakefulness are under the influence of the circadian pacemaker in the suprachiasmatic nucleus, and the set-point for the circadian pacemaker is revealed by the time of onset of the secretion of melatonin under dim light conditions ( ...
Full textCite
Journal articleAnnu Int Conf IEEE Eng Med Biol Soc · July 2018
Down syndrome is one of the health disorders that interferes with regular and healthy sleep. Most children with Down syndrome are referred to a sleep clinic for the assessment of the severity of their apnea. Regular polysomnography based assessment of apne ...
Full textLink to itemCite
Journal articleJ Consult Clin Psychol · March 2018
OBJECTIVE: Insomnia and major depressive disorders (MDD) often co-occur, and such comorbidity has been associated with poorer outcomes for both conditions. However, individual differences in depressive symptom trajectories during and after treatment are po ...
Full textLink to itemCite
Journal articleJ Affect Disord · February 2018
BACKGROUND: Epidemiological data have demonstrated seasonal and circadian patterns of suicidal deaths. Several reviews and meta-analyses have confirmed the relationship between sleep disturbance and suicidality. However, these reviews/meta-analyses have no ...
Full textLink to itemCite
Journal articleIEEE Sensors Journal · January 15, 2018
Hibernation is a unique metabolic adaptation employed by several animal species for survival where its study would further enhance our understanding of metabolic disorders, such as diabetes and obesity. As a primate animal with close genetic ties to humans ...
Full textCite
Journal articleJ Clin Psychiatry · 2018
OBJECTIVE: To provide expert recommendations for the safe and effective application of repetitive transcranial magnetic stimulation (rTMS) in the treatment of major depressive disorder (MDD). PARTICIPANTS: Participants included a group of 17 expert clinici ...
Full textLink to itemCite
Journal articleBrain Stimul · 2018
BACKGROUND: Evidence suggests that transcranial Direct Current Stimulation (tDCS) has antidepressant effects in unipolar depression, but there is limited information for patients with bipolar depression. Additionally, prior research suggests that brain der ...
Full textLink to itemCite
Journal articleInt J Neuropsychopharmacol · August 1, 2017
BACKGROUND: We evaluated the orexin receptor antagonist filorexant (MK-6096) for treatment augmentation in patients with major depressive disorder. METHODS: We conducted a 6-week, double-blind, placebo-controlled, parallel-group, Phase II, proof-of-concept ...
Full textLink to itemCite
Journal articleClin Neurophysiol · August 2017
OBJECTIVE: Delirium is a common post-operative complication associated with significant costs, morbidity, and mortality. We sought sleep/EEG predictors of delirium present prior to delirium symptoms to facilitate developing and targeting therapies. METHODS ...
Full textLink to itemCite
Journal articleAm J Hum Biol · July 8, 2017
OBJECTIVES: We studied sleep in a rural population in Madagascar to (i) characterize sleep in an equatorial small-scale agricultural population without electricity, (ii) assess whether sleep is linked to noise levels in a dense population, and (iii) examin ...
Full textLink to itemCite
Journal articleAm J Geriatr Psychiatry · July 2017
OBJECTIVE: Suvorexant is an orexin receptor antagonist approved for treating insomnia at doses of 10-20 mg. Previously reported phase III results showed that suvorexant was effective and well-tolerated in a combined-age population (elderly and nonelderly a ...
Full textLink to itemCite
Journal articleAnaesthesia · June 2017
Previous pilot work has established an association between obstructive sleep apnoea and the development of acute postoperative delirium , but it remains unclear to what extent this risk factor is modifiable in the 'real world' peri-operative setting. In a ...
Full textLink to itemCite
Journal articlePsychopharmacology (Berl) · June 2017
RATIONALE: Sex-related differences in the clinical profiles of some insomnia medications have been previously reported. OBJECTIVE: To evaluate the clinical profile of suvorexant, a novel orexin receptor antagonist approved for treating insomnia at doses up ...
Full textLink to itemCite
Journal articleSleep · April 1, 2017
STUDY OBJECTIVE: To compare cognitive behavioral therapy for insomnia (CBT-I) + antidepressant medication (AD) against treatments that target solely depression or solely insomnia. DESIGN: A blinded, randomized split-plot experimental study. SETTING: Two ur ...
Full textLink to itemCite
Journal articleJ Clin Sleep Med · February 15, 2017
STUDY OBJECTIVES: To determine if patients with childhood onsets (CO) of both major depression and insomnia disorder show blunted depression and insomnia treatment responses to concurrent interventions for both disorders compared to those with adult onsets ...
Full textLink to itemCite
Journal articleJ Clin Sleep Med · February 15, 2017
INTRODUCTION: The purpose of this guideline is to establish clinical practice recommendations for the pharmacologic treatment of chronic insomnia in adults, when such treatment is clinically indicated. Unlike previous meta-analyses, which focused on broad ...
Full textLink to itemCite
Journal articleSleep Health · February 2017
OBJECTIVES: To provide evidence-based recommendations and guidance to the public regarding indicators of good sleep quality across the life-span. METHODS: The National Sleep Foundation assembled a panel of experts from the sleep community and representativ ...
Full textLink to itemCite
Journal articleAm J Psychiatry · January 1, 2017
OBJECTIVE: Insomnia is associated with increased risk for suicide. The Food and Drug Administration (FDA) has mandated that warnings regarding suicide be included in the prescribing information for hypnotic medications. The authors conducted a review of th ...
Full textLink to itemCite
Journal articleSleep · January 1, 2017
STUDY OBJECTIVES: This study examined whether individuals with insomnia and objective short sleep duration <6 h, a subgroup with greater risks of adverse health outcomes, differ in their response to cognitive-behavioral therapy for insomnia (CBT-I) when co ...
Full textLink to itemCite
Journal articleSleep · January 1, 2017
STUDY OBJECTIVES: Nocturia, voids which disturb sleep, is the most common cause of awakenings and is associated with daytime sleepiness. Because the standard treatments for the most common causes of nocturia are relatively ineffective, many treated patient ...
Full textLink to itemCite
Journal articleClin Psychol Rev · December 2016
BACKGROUND: Biological mechanisms underlying symptom and prognostic heterogeneity in Attention-Deficit/Hyperactivity Disorder (ADHD) are unclear. Sleep impacts neurocognition and daytime functioning and is disrupted in ADHD, yet little is known about sleep ...
Full textLink to itemCite
Journal articleCurrent Sleep Medicine Reports · December 1, 2016
Certain medications exhibit sex-specific pharmacological profiles. It is, therefore, imperative to understand their unique pharmacokinetic properties to optimize women’s health. Two such medications that are commonly used in sleep medicine are zolpidem and ...
Full textCite
Journal articleTrends Pharmacol Sci · November 2016
Serotonin transporter (SERT) inhibitors treat depression by elevating brain extracellular 5-hydroxytryptamine (5-HTExt). However, only one-third of patients respond adequately. Treatment-resistant depression (TRD) is a major unmet need. Interestingly, elev ...
Full textLink to itemCite
Journal articleDepress Anxiety · October 2016
Kappa-opioid receptor (KOR) antagonists are currently being considered for the treatment of a variety of neuropsychiatric conditions, including depressive, anxiety, and substance abuse disorders. A general ability to mitigate the effects of stress, which c ...
Full textLink to itemCite
Journal articleJ Clin Sleep Med · September 15, 2016
STUDY OBJECTIVES: Suvorexant is an orexin receptor antagonist approved for treating insomnia at a maximum dose of 20 mg. Phase-3 trials evaluated two age-adjusted (non-elderly/elderly) dose-regimes of 40/30 mg and 20/15 mg with the primary focus on 40/30 m ...
Full textLink to itemCite
Journal articleSleep · September 9, 2016
STUDY OBJECTIVES: This study examined whether individuals with insomnia and objective short sleep duration <6h, a subgroup with greater risks of adverse health outcomes, differ in their response to cognitive behavioral therapy for insomnia (CBT-I) when com ...
Link to itemCite
Journal articleSleep · September 9, 2016
STUDY OBJECTIVES: Nocturia, voids which disturb sleep, is the most common cause of awakenings and is associated with daytime sleepiness. Because the standard treatments for the most common causes of nocturia are relatively ineffective, many treated patient ...
Link to itemCite
Journal articlePrim Care Companion CNS Disord · September 8, 2016
BACKGROUND: Brexpiprazole is a serotonin-dopamine activity modulator. We evaluated the effects of adjunctive treatment with brexpiprazole on sleep disturbances in patients with DSM-IV-TR major depressive disorder (MDD) and inadequate response to antidepres ...
Full textLink to itemCite
Journal articleR Soc Open Sci · August 2016
During hibernation, critical physiological processes are downregulated and thermogenically induced arousals are presumably needed periodically to fulfil those physiological demands. Among the processes incompatible with a hypome tabolic state is sleep. How ...
Full textLink to itemCite
Journal articleSleep · May 1, 2016
STUDY OBJECTIVES: To examine the relationship between hypertension prevalence in individuals with insomnia who have short total sleep duration < 6 h or sleep duration ≥ 6 h, using both objective and subjective measures of total sleep duration. METHODS: Usi ...
Full textLink to itemCite
Journal articleHum Psychopharmacol · May 2016
BACKGROUND: Lurasidone, an atypical antipsychotic, is a potent 5-HT7 antagonist and D2 , 5-HT2A antagonist, and 5-HT1A partial agonist. As such, lurasidone would be expected to modulate sleep and circadian function but there have been no human studies of t ...
Full textLink to itemCite
Journal articleJ Clin Psychiatry · April 2016
OBJECTIVE: Sleep disturbances are common among veterans with chronic military-related posttraumatic stress disorder (PTSD). This article reports the results of a multicenter clinical trial that explored the clinical correlates of reported sleep impairment ...
Full textLink to itemCite
Journal articleJ Clin Psychiatry · April 2016
Insomnia is a common feature of both medical and psychiatric disorders. Whether as a symptom of an illness or as a comorbid disorder, insomnia worsens patient outcomes related to quality of life, functioning, workplace productivity, and health care expendi ...
Full textLink to itemCite
Journal articleTrials · March 3, 2016
BACKGROUND: Chronic insomnia is a prevalent disorder associated with significant psychosocial, health, and economic impacts. Cognitive behavioral therapies (CBTs) and benzodiazepine receptor agonist (BzRA) medications are the most widely supported therapeu ...
Full textOpen AccessLink to itemCite
Journal articleBiol Psychiatry · January 15, 2016
BACKGROUND: Suvorexant is an orexin receptor antagonist for treatment of insomnia. We report results from two pivotal phase 3 trials. METHODS: Two randomized, double-blind, placebo-controlled, parallel-group, 3-month trials in nonelderly (18-64 years) and ...
Full textLink to itemCite
Journal articleEvol Med Public Health · 2016
Sleep is essential to cognitive function and health in humans, yet the ultimate reasons for sleep-i.e. 'why' sleep evolved-remain mysterious. We integrate findings from human sleep studies, the ethnographic record, and the ecology and evolution of mammalia ...
Full textLink to itemCite
Journal articlePsychiatr Clin North Am · December 2015
Many insomnia medications with high specificity have become available recently. They provide a window into the clinical effects of modulating specific brain systems and establish a new guiding principal for conceptualizing insomnia medications: "mechanism ...
Full textLink to itemCite
Journal articleNat Rev Dis Primers · September 3, 2015
Insomnia disorder affects a large proportion of the population on a situational, recurrent or chronic basis and is among the most common complaints in medical practice. The disorder is predominantly characterized by dissatisfaction with sleep duration or q ...
Full textLink to itemCite
Journal articleNeuropsychopharmacology · August 2015
Electroconvulsive therapy (ECT) at conventional current amplitudes (800-900 mA) is highly effective but carries the risk of cognitive side effects. Lowering and individualizing the current amplitude may reduce side effects by virtue of a less intense and m ...
Full textLink to itemCite
Journal articleJ Clin Psychiatry · August 2015
Research into the sleep-wake cycle has provided new treatment targets for patients with insomnia as well as a better understanding of how medications affect sleep processes. Current insomnia medications, including benzodiazepines and nonbenzodiazepines, fo ...
Full textLink to itemCite
Journal articleSleep Med · July 2015
OBJECTIVE: Esmirtazapine (Org 50081), a medication that binds with high affinity to serotonin 5-HT2A and histamine-1 receptors, was evaluated as a potential treatment for insomnia. METHODS: Adults with primary insomnia were treated with esmirtazapine (3.0 ...
Full textLink to itemCite
Journal articleClin Trials · June 2015
BACKGROUND/AIMS: Suicide is a major public health concern, yet there are very few randomized clinical trials that have been conducted to reduce suicidal ideation in patients at risk of suicide. We describe the rationale and refinements of such a trial that ...
Full textLink to itemCite
Journal articleInnovations in Clinical Neuroscience · March 1, 2015
Once a molecule has been characterized as engaging an identified target at the appropriate location (affinity and potency), the next step involves designing experiments that will determine its pharmacodynamic activities both for efficacy (on target) and sa ...
Cite
Journal articleFrontiers in Human Neuroscience · February 4, 2015
Measuring neuronal activity with electrophysiological methods may be useful in detecting neurological dysfunctions, such as mild traumatic brain injury (mTBI).This approach may be particularly valuable for rapid detection in at-risk populations including m ...
Full textCite
Journal articleBrain Stimul · 2015
BACKGROUND: Transcranial Magnetic Stimulation (TMS) customarily uses high-field electromagnets to achieve therapeutic efficacy in Major Depressive Disorder (MDD). Low-field magnetic stimulation also may be useful for treatment of MDD, with fewer treatment- ...
Full textLink to itemCite
Journal articleSchizophr Res · December 2014
BACKGROUND: Insomnia is frequent in schizophrenia and may contribute to cognitive impairment as well as overuse of weight inducing sedative antipsychotics. We investigated the effects of eszopiclone on sleep and cognition for patients with schizophrenia-re ...
Full textLink to itemCite
Journal articleJ Affect Disord · October 2014
BACKGROUND: There is growing research interest in studying motivational deficits in different neuropsychiatric disorders because these symptoms appear to be more common than originally reported and negatively impact long-term functional outcomes. However, ...
Full textLink to itemCite
Journal articleJ ECT · June 2014
For many patients with neuropsychiatric illnesses, standard psychiatric treatments with mono or combination pharmacotherapy, psychotherapy, and transcranial magnetic stimulation are ineffective. For these patients with treatment-resistant neuropsychiatric ...
Full textOpen AccessLink to itemCite
Journal articleSleep · June 1, 2014
STUDY OBJECTIVES: Insomnia, which is very common in patients with chronic low back pain (LBP), has long been viewed as a pain symptom that did not merit specific treatment. Recent data suggest that adding insomnia therapy to pain-targeted treatment should ...
Full textLink to itemCite
Journal articleJ Psychopharmacol · May 2014
INTRODUCTION: We sought to test the hypothesis that improvements in sleep might mediate treatment-related improvements in daytime symptoms of post-traumatic stress disorder (PTSD). We evaluated whether changes in sleep occurring on the first night of tiaga ...
Full textOpen AccessLink to itemCite
Journal articleLancet Neurol · May 2014
BACKGROUND: Suvorexant (MK-4305) is an orexin receptor antagonist shown to be efficacious for insomnia over 3 months. We aimed to assess its clinical profile during and after 1 year of treatment. METHODS: We did a randomised, placebo-controlled, parallel-g ...
Full textLink to itemCite
Journal articleSleep Breath · March 2014
INTRODUCTION: Obstructive sleep apnea (OSA) is a medical disorder strongly associated with multiple comorbidities and postoperative complications. Current evidence suggests that OSA disturbs fundamental biochemical processes, leading to low-grade systemic ...
Full textLink to itemCite
Journal articleJ Clin Sleep Med · February 15, 2014
STUDY OBJECTIVE: To assess the effect of armodafinil on task-related prefrontal cortex activation using functional magnetic resonance imaging (fMRI) in patients with obstructive sleep apnea (OSA) and excessive sleepiness despite continuous positive airway ...
Full textLink to itemCite
Journal articleDev Neurobiol · February 2014
Despite recent advances in understanding the molecular mechanisms of autism spectrum disorders (ASD), the current treatments for these disorders are mostly focused on behavioral and educational approaches. The considerable clinical and molecular heterogene ...
Full textLink to itemCite
Journal articleAIDS Rev · 2014
The prevalence of insomnia in the HIV-seropositive population is estimated to be 29-97%, far greater than the 10% general population prevalence. We carried out a systematic review to assess whether the prevalence of insomnia is indeed higher in HIV-seropos ...
Link to itemCite
Journal articleSleep Med Clin · September 1, 2013
A number of medications are available for treating patients with insomnia. These medications include agents approved as insomnia therapies by the U.S. Food and Drug Administration (FDA), agents approved by the FDA for another condition that are used "off-l ...
Full textLink to itemCite
Journal articleSleep Med Rev · August 2013
The pharmacologic management of insomnia has long been dominated by agents that facilitate gamma amino butyric acid inhibition. These agents have served as the clinical model for understanding the pharmacodynamic effects of insomnia agents according to whi ...
Full textLink to itemCite
Journal articleSleep · August 1, 2013
OBJECTIVE: To examine the association between physiological hyperarousal and response accuracy on reaction time tasks among individuals with insomnia. DESIGN AND SETTING: This study was conducted at affiliated Veterans Administration (VA) and academic medi ...
Full textLink to itemCite
Journal articleInt Urogynecol J · March 2013
INTRODUCTION AND HYPOTHESIS: Can diary-derived bladder and sleep measurements differentiate individuals with overactive bladder syndrome (OAB) from individuals with primary insomnia and healthy controls? METHODS: Bladder- and sleep-diary data were compared ...
Full textLink to itemCite
Journal articleSleep · February 1, 2013
STUDY OBJECTIVES: To evaluate efficacy and safety of 3.5-mg zolpidem tartrate sublingual tablets (ZST) on latency to sleep onset after middle-of-the-night (MOTN) awakenings in patients with insomnia characterized by difficulty returning to sleep after MOTN ...
Full textLink to itemCite
Journal articlePsychiatry Res · January 30, 2013
As they alleviate major depressive disorder, antidepressant therapies may improve associated sleep disturbances, but may also have inherent sedating or activating properties. We examined sleep changes during a multicenter, sham-controlled, trial of transcr ...
Full textLink to itemCite
Journal articlePLoS One · 2013
STUDY OBJECTIVES: It has long been suspected that sleep is important for regulating body temperature and metabolic-rate. Hibernation, a state of acute hypothermia and reduced metabolic-rate, offers a promising system for investigating those relationships. ...
Full textOpen AccessLink to itemCite
Journal articleClin Neurophysiol · December 2012
OBJECTIVE: There is a high prevalence of insomnia in HIV-seropositive patients. Insomnia is associated with poorer disease outcomes, cognitive impairment and HIV-associated dementia. However there is limited data characterizing the type of sleep disturbanc ...
Full textLink to itemCite
Journal articleNeurol Clin · November 2012
There is growing experimental evidence that the relationship between psychiatric disorders and sleep is complex and includes bidirectional causation. This article provides the evidence that supports this point of view, reviewing data on sleep disturbances ...
Full textLink to itemCite
Journal articleJ Clin Psychiatry · August 2012
Shift work disorder (SWD) is a circadian rhythm sleep disorder characterized by insomnia and excessive sleepiness. SWD, which is estimated to affect 10% of people who work night or rotating shifts, can have serious consequences such as accidents, loss of p ...
Full textLink to itemCite
Journal articleSleep Med · June 2012
BACKGROUND: Insomnia marked by sleep maintenance difficulty is extremely prevalent. Yet, problems staying asleep have been relatively neglected as a research focus compared to problems falling asleep. Insomnia treatment studies typically have not required ...
Full textLink to itemCite
Journal articleNeurology · May 15, 2012
OBJECTIVE: To assess the prevalence and comorbid conditions of nocturnal wandering with abnormal state of consciousness (NW) in the American general population. METHODS: Cross-sectional study conducted with a representative sample of 19,136 noninstitutiona ...
Full textLink to itemCite
Journal articleAnesthesiology · April 2012
BACKGROUND: Postoperative delirium, a common complication in the elderly, can occur following any type of surgery and is associated with increased morbidity and mortality; it may also be associated with subsequent cognitive problems. Effective therapy for ...
Full textLink to itemCite
Journal articleJ Clin Psychiatry · February 2012
It is estimated that 15 to 25% of the U.S. labor force works night, evening, or rotating shifts. These non-traditional schedules can affect the circadian rhythm, a self-sustained rhythm of biological processes that plays an important role in modulating sle ...
Full textLink to itemCite
Journal articleSleep · February 1, 2012
STUDY OBJECTIVES: To present an expert consensus, standardized, patient-informed sleep diary. METHODS AND RESULTS: Sleep diaries from the original expert panel of 25 attendees of the Pittsburgh Assessment Conference(1) were collected and reviewed. A smalle ...
Full textLink to itemCite
Journal articlePLoS One · 2012
A number of antiepileptic medications that modulate GABA(A) mediated synaptic transmission are anxiolytic. The loop diuretics furosemide (Lasix) and bumetanide (Bumex) are thought to have antiepileptic properties. These drugs also modulate GABA(A) mediated ...
Full textLink to itemCite
Journal articleJournal of Aggression Maltreatment and Trauma · January 1, 2012
The few pharmacological treatments shown to be effective in reducing sleep disturbance in posttraumatic stress disorder (PTSD) might work through normalization of rapid eye movement (REM). However, evidence of REM sleep disturbance in PTSD has been inconsi ...
Full textCite
Journal articlePrim Care Companion CNS Disord · 2012
OBJECTIVE: The purpose of this post hoc analysis was to compare the treatment effect size of eszopiclone 3 mg for insomnia in patients with a diagnosis of primary insomnia and in several of the psychiatric and medical conditions that are most commonly como ...
Full textLink to itemCite
Journal articleSchizophr Res · December 2011
BACKGROUND: Sleep difficulties are common in schizophrenia, however these complaints are often overshadowed by more prominent clinical concerns. The point prevalence of insomnia in this population is not well documented. Poor sleep is associated with lower ...
Full textLink to itemCite
Journal articleSleep · December 1, 2011
OBJECTIVE: Fatigue is a pervasive symptom associated with HIV, resulting in significant functioning impairment; but little is known about its etiology or treatment. In patients with primary insomnia, data have shown improvement in fatigue following success ...
Full textLink to itemCite
Journal articleBiol Psychiatry · October 15, 2011
BACKGROUND: Previous functional magnetic resonance imaging studies have shown strong correlations between cue-elicited craving for cigarettes and activation of the superior frontal gyrus (SFG). Repetitive transcranial magnetic stimulation (rTMS) offers a n ...
Full textLink to itemCite
Journal articleArch Gen Psychiatry · October 2011
CONTEXT: Distinctive diagnostic classification schemes for insomnia diagnoses are available, but the optimal insomnia nosology has yet to be determined. OBJECTIVES: To test the reliability and validity of insomnia diagnoses listed in the American Psychiatr ...
Full textLink to itemCite
Journal articleSleep · October 1, 2011
STUDY OBJECTIVES: To evaluate the efficacy and safety of doxepin (DXP) 3 mg and 6 mg in adults diagnosed with primary insomnia. DESIGN AND METHODS: The study was a randomized, double-blind, parallel-group, placebo-controlled trial. Patients meeting DSM-IV- ...
Full textLink to itemCite
Journal articleJ Psychiatr Res · September 2011
Assessing for clinical levels of anxiety is crucial, as comorbid insomnias far outnumber primary insomnias (PI). Such assessment is complex since those with Anxiety Disorders (AD) and those with PI have overlapping symptoms. Because of this overlap, we nee ...
Full textLink to itemCite
Journal articleCurr Pharm Des · 2011
Insomnia is a highly prevalent condition, and due to ongoing demand from patients suffering with this condition, new pharmacological treatments are actively being sought. As our neurophysiological understanding of insomnia grows, so too do the available tr ...
Full textLink to itemCite
Journal articleJ Psychopharmacol · November 2010
Sleep disorders are common in the general population and even more so in clinical practice, yet are relatively poorly understood by doctors and other health care practitioners. These British Association for Psychopharmacology guidelines are designed to add ...
Full textLink to itemCite
Journal articleSleep · November 2010
STUDY OBJECTIVES: to evaluate the efficacy and safety of doxepin 1 mg and 3 mg in elderly subjects with chronic primary insomnia. DESIGN AND METHODS: the study was a randomized, double-blind, parallel-group, placebo-controlled trial. Subjects meeting DSM-I ...
Full textLink to itemCite
Journal articlePsychooncology · October 2010
OBJECTIVE: Cancer and its treatments disturb sleep-wake functioning; however, there is little information available on the characteristics and consequences of sleep problems associated with cancer. As part of an effort to improve measurement of sleep-wake ...
Full textLink to itemCite
Journal articleBrain Stimul · October 2010
BACKGROUND: Although transcranial magnetic stimulation (TMS) can be an effective acute antidepressant treatment, few studies systematically examine persistence of benefit. OBJECTIVE: We assessed the durability of antidepressant effect after acute response ...
Full textLink to itemCite
Journal articleJ Clin Sleep Med · August 15, 2010
STUDY OBJECTIVES: To determine if vestibular stimulation is an effective therapy for transient insomnia in a sleep phase advance model. DESIGN: Multi-site, double-blind, randomized, parallel-group, sham-controlled trial SETTING: This study was carried out ...
Link to itemCite
Journal articleJ Clin Sleep Med · August 15, 2010
STUDY OBJECTIVES: Insomnia is associated with poor health related quality of life (HRQOL) in depressed patients. Prior clinical trials of hypnotic treatment of insomnia in depressed patients have shown improvement in HRQOL, but in these studies HRQOL was r ...
Link to itemCite
Journal articleJ Urol · August 2010
PURPOSE: Nocturia, a common symptom of overactive bladder syndrome, is associated with substantial adverse consequences and yet its pathophysiology has hardly been studied and the capacity to treat it remains limited. We established methods to study the ph ...
Full textLink to itemCite
Journal articleSleep · May 2010
STUDY OBJECTIVES: Determine the relationship of non-rapid eye movement (NREM) electroencephalographic (EEG) spectral measures and the response to cognitive behavioral therapy (CBT) in primary insomnia (PI). DESIGN: Patients with PI were randomly assigned t ...
Full textLink to itemCite
Journal articleSleep Med · March 2010
OBJECTIVE: Nocturnal awakenings are one of the most prevalent sleep disturbances in the general population. Little is known, however, about the frequency of these episodes and how difficulty resuming sleep once awakened affects subjective sleep quality and ...
Full textLink to itemCite
Journal articleSleep · February 2010
BACKGROUND: Longer-term pharmacologic studies for insomnia in older individuals are sparse. OBJECTIVE: To evaluate the efficacy and safety of 12 weeks of nightly eszopiclone in elderly outpatients with insomnia. METHODS: Participants (65-85 years) met DSM- ...
Full textLink to itemCite
Journal articlePsychiatric Times · January 1, 2010
Insomnia is a highly prevalent and costly condition. It is underdiagnosed and many patients remain untreated. All patients should be asked about their sleep-related health. If the patient has sleep difficulties accompanied by impairment in physical or cogn ...
Cite
Journal articleJ Clin Psychiatry · January 2010
OBJECTIVE: Treatment of excessive sleepiness in the context of obstructive sleep apnea (OSA) may be particularly difficult in those with depression because depression and/or antidepressant medications may cause sleepiness and fatigue in addition to that du ...
Full textLink to itemCite
Journal articleSleep Med Rev · August 2009
For many years practitioners have had limited data from double-blind, placebo-controlled studies to guide the types of decision-making needed to optimally manage patients with insomnia in clinical practice. However, in recent years there has been a great i ...
Full textLink to itemCite
Journal articleJ Clin Sleep Med · June 15, 2009
Insomnia is common in human immunodeficiency virus (HIV) seropositive populations. Some studies have estimated as many as 70% of HIV patients experience insomnia at some point during their illness. Insomnia has been linked to reduced quality of life as wel ...
Link to itemCite
Journal articleJ Psychiatr Res · February 2009
BACKGROUND: Due to concerns about overlapping symptomatology between medical conditions and depression, the validity of the beck depression inventory (BDI-II) has been assessed in various medical populations. Although major depressive disorder (MDD) and pr ...
Full textLink to itemCite
Journal articleNeuropsychopharmacology · January 2009
Randomized controlled trials support the antidepressant efficacy of transcranial magnetic stimulation (TMS); however, there is individual variability in the magnitude of response. Examination of response predictors has been hampered by methodological limit ...
Full textLink to itemCite
Journal articleClin Neurophysiol · December 2008
OBJECTIVE: Slow-wave activity (SWA) is believed to be a fundamental measure of sleep homeostasis and is frequently characterized as an exponentially declining periodic dynamical system. The objective of this study is to carry out the first rigorous statist ...
Full textLink to itemCite
Journal articlePsychiatric Annals · September 1, 2008
There is a need for objective measures of insomnia that can be used in diagnosis and outcome assessment. Although PSG is a valuable outcome assessment tool in a selected subset of insomnia patients, we lack measures with diagnostic utility and that can ref ...
Cite
Journal articleSleep Med · September 2008
Despite being used commonly in sleep medicine, the term "sleep quality" has not been rigorously defined. The purpose of this article is to consider objective measures of the subjective "sleep quality" experience. In order to do so, it was necessary to choo ...
Full textLink to itemCite
Journal articleSleep · May 2008
OBJECTIVE: To examine psychomotor (reaction time) performance deficits and their relation to subjective and objective sleep measures among individuals with primary insomnia (PI). DESIGN AND SETTING: This study was conducted at affiliated VA and academic me ...
Full textLink to itemCite
Journal articleArch Gen Psychiatry · May 2008
CONTEXT: Insomnia and generalized anxiety disorder (GAD) are prevalent disorders that may coexist. OBJECTIVE: To determine the efficacy of eszopiclone combined with escitalopram oxalate in treating insomnia comorbid with GAD. DESIGN: Double-blind, randomiz ...
Full textLink to itemCite
Journal articleInt Clin Psychopharmacol · May 2008
Schizophrenia is often accompanied by sleep problems. Evidence exists that these sleep difficulties have significant effects on individuals with this disorder. The mainstay of treatment for this condition is the administration of medications that have effe ...
Full textLink to itemCite
Journal articleJ Clin Sleep Med · April 15, 2008
We report two cases in which amnestic sleep related eating disorder (SRED) occurred with extended-release zolpidem but not with the immediate-release formulation. These cases illustrate how even relatively small differences such as formulation can affect t ...
Link to itemCite
Journal articleAnn Clin Psychiatry · 2008
INTRODUCTION: While the precise role of sleep in maintaining optimal health and function remains unknown, it is clear that disturbances of sleep have a profound impact on the lives of affected individuals. In psychiatric disorders, not only is there a rela ...
Full textLink to itemCite
Journal articleSleep · January 2008
STUDY OBJECTIVES: To evaluate long-term efficacy and safety of zolpidem extended-release 3 to 7 nights/week for chronic primary insomnia. DESIGN: Multicenter, 25-week, phase IIIb, randomized, double-blind, placebo-controlled, parallel-group. SETTING: Outpa ...
Full textLink to itemCite
Journal articleSleep · August 2007
STUDY OBJECTIVES: To evaluate 6 months' eszopiclone treatment upon patient-reported sleep, fatigue and sleepiness, insomnia severity, quality of life, and work limitations. DESIGN: Randomized, double blind, controlled clinical trial. SETTING: 54 research s ...
Full textLink to itemCite
Journal articleCNS Spectr · July 2007
Insomnia is a disorder characterized by chronic sleep disturbance associated with daytime disability or distress, such as memory impairment and fatigue, that occurs despite adequate opportunity for sleep. Insomnia may present as difficulty falling/staying ...
Link to itemCite
Journal articlePrimary Psychiatry · July 1, 2007
Insomnia is a disorder characterized by chronic sleep disturbance associated with daytime disability or distress, such as memory impairment and fatigue, that occurs despite adequate opportunity for sleep. Insomnia may present as difficulty falling/staying ...
Cite
Journal articlePsychosom Med · June 2007
OBJECTIVE: To examine the relationships among the variable number of tandem repeats in the monoamine oxidase-A linked polymorphic region allelic variation (MAOA-uVNTR) and the symptoms of depression and sleep quality. The monoamine oxidase-A (MAOA) gene, w ...
Full textLink to itemCite
Journal articlePsychiatry Clin Neurosci · June 2007
Central pontine and extrapontine myelinolysis (CPEM) are rare conditions usually associated with rapid correction of hyponatremia. Neurologic complications are the usual sequelae although neuropsychiatric features are rare. Described herein are unusual psy ...
Full textLink to itemCite
Journal articleCurrent Psychiatry Reviews · May 1, 2007
Objectives: Depressed patients often have insomnia, daytime sleepiness, and/or changes in sleep architecture. These sleep/wake changes are associated with diminished quality of life, impaired function, diminished treatment response and greater risk of rela ...
Full textCite
Journal articleJ Clin Sleep Med · February 15, 2007
STUDY OBJECTIVES: Impairments in health, function, and quality of life (QOL) are a central feature of insomnia, yet insomnia treatment is targeted solely to improving problems falling and staying asleep. It is not even known if the nonsleep deficits improv ...
Link to itemCite
Journal articleJ Clin Sleep Med · February 15, 2007
BACKGROUND: Insomnia and major depressive disorder (MDD) may coexist. This study evaluated hypnotic discontinuation effects following an 8-week placebo-controlled study of eszopiclone/fluoxetine cotherapy in patients with insomnia and comorbid MDD. METHODS ...
Link to itemCite
Journal articleJ Clin Psychiatry · February 2007
OBJECTIVE: A number of pharmacologic studies have documented that insomnia is among the most commonly reported residual symptoms after remission from depression. Residual symptoms after remission are particularly relevant because these symptoms confer grea ...
Full textLink to itemCite
Journal articleCNS Spectrums · January 1, 2007
Insomnia is a disorder characterized by chronic sleep disturbance associated with daytime disability or distress, such as memory impairment and fatigue, that occurs despite adequate opportunity for sleep. Insomnia may present as difficulty falling/staying ...
Full textCite
Journal articlePsychosom Med · 2007
OBJECTIVE: To test the hypothesis that allelic variation in 5HTT gene-linked polymorphic region (5-HTTLPR) genotype was associated with sleep quality (Pittsburgh Sleep Quality Index, PSQI) as a main effect and as moderated by the chronic stress of caregivi ...
Full textLink to itemCite
Journal articlePsychiatr Clin North Am · December 2006
Understanding of the relationship between co-occurring sleep and psychiatric disorders has undergone a radical change. The longstanding perspective that sleep problems invariably are a symptom of a psychiatric disorder is giving way to understanding that c ...
Full textLink to itemCite
Journal articleJ Clin Sleep Med · October 15, 2006
STUDY OBJECTIVES: To assess the efficacy of zaleplon 10 mg and zolpidem 10 mg administered during experimental middle-of-the-night awakenings in patients with sleep-maintenance insomnia using objective polysomnographic measures and to assess daytime residu ...
Link to itemCite
Journal articleSleep Medicine Clinics · September 1, 2006
A review of studies of the treatment of insomnia occurring in association with other psychiatric disorders suggests that the secondary insomnia model fails to explain adequately the relationship between insomnia and the associated conditions and also fails ...
Full textCite
Journal articleCurr Med Res Opin · September 2006
OBJECTIVE: To evaluate the safety and efficacy of eszopiclone 2 mg in elderly patients (aged 64-86 years) with chronic insomnia. METHODS: This was a randomized, double-blind, placebo-controlled 2-week study. Patients meeting DSM-IV criteria for primary ins ...
Full textLink to itemCite
Journal articleBiol Psychiatry · June 1, 2006
BACKGROUND: Insomnia and major depressive disorder (MDD) can coexist. This study evaluated the effect of adding eszopiclone to fluoxetine. METHODS: Patients who met DSM-IV criteria for both MDD and insomnia (n = 545) received morning fluoxetine and were ra ...
Full textLink to itemCite
Journal articleJ Clin Sleep Med · January 15, 2006
INTRODUCTION: This study evaluated dose-response effects of tiagabine on sleep in adults with primary insomnia. METHODS: Men and women with primary insomnia (DSM-IV-TR) were randomly assigned to receive tiagabine 4, 6, 8, 10 mg or placebo in a randomized, ...
Link to itemCite
Journal articleJournal for Nurse Practitioners · January 1, 2006
Chronic insomnia is common among primary care patients and often necessitates long-term management. The available treatment options for the clinical care of such patients are limited. Medication management is the most common therapy for this condition; how ...
Full textCite
Journal articleArch Intern Med · November 28, 2005
BACKGROUND: Insomnia is common and debilitating to fibromyalgia (FM) patients. Cognitive-behavioral therapy (CBT) is effective for many types of patients with insomnia, but has yet to be tested with FM patients. This study compared CBT with an alternate be ...
Full textLink to itemCite
Journal articleSleep Med · November 2005
BACKGROUND AND PURPOSE: A double-blind placebo-controlled study of eszopiclone found significant, sustained improvement in sleep and daytime function. The 6-month open-label extension phase is described herein. PATIENTS AND METHODS: Adults (21-64) with pri ...
Full textLink to itemCite
Journal articleInt J Clin Pharmacol Ther · August 2005
OBJECTIVE: Sleep parameters commonly improve during placebo treatment in insomnia clinical trials. We examined whether the improvement seen with placebo was related to taking pills or other non-specific factors. METHOD: 95 insomniacs took either a placebo ...
Full textLink to itemCite
Journal articleJ Am Geriatr Soc · July 2005
There is a need for newer, more clinically useful classifications for insomnia. Identification of specific subtypes of insomnia helps anchor research, allows for prediction of prognosis/course of the condition, and may allow for individualization of treatm ...
Full textLink to itemCite
Journal articleInternational Journal of Clinical Pharmacology and Therapeutics · 2005
Objective: Sleep parameters commonly improve during placebo treatment in insomnia clinical trials. We examined whether the improvement seen with placebo was related to taking pills or other non-specific factors. Method: 95 insomniacs took either a placebo ...
Cite
Journal articleJ Clin Psychiatry · August 2004
INTRODUCTION: While it is common practice that hypnotics are used on a non-nightly basis, few investigations have been undertaken to evaluate the efficacy of the intermittent dosing strategy. The present study was designed to further evaluate this issue wi ...
Full textLink to itemCite
Journal articleJ Clin Psychiatry · 2004
Featured Publication
A particular challenge in the treatment of insomnia is management of chronic insomnia, which occurs in a substantial portion of the population. A number of factors suggest the importance of identifying this condition as distinct from short-term insomnia in ...
Link to itemCite
Journal articleClin Cornerstone · 2004
Depression and insomnia are both significantly more prevalent in women than in men. Risks appear linked to fluctuations and transitions in gonadal hormones during various phases of women's lives, with the risk of depression greatest during the period from ...
Full textLink to itemCite
Journal articleSleep · November 1, 2003
Featured Publication
STUDY OBJECTIVES: To determine the long-term efficacy of eszopiclone in patients with chronic insomnia. DESIGN: Randomized, double-blind, multicenter, placebo-controlled. SETTING: Out-patient, with monthly visits. PATIENTS: Aged 21 to 69 years meeting DSM ...
Full textLink to itemCite
Journal articleSleep Med Rev · June 2003
Featured Publication
Among the range of primary insomnia subtypes, those assigned such labels as subjective insomnia or sleep state misperception historically have been among the most intriguing yet challenging to understand and manage clinically. Such patients who produce see ...
Full textLink to itemCite
Journal articleJ Neuropsychiatry Clin Neurosci · 2003
Featured Publication
The authors retrospectively compared the seizure duration, ictal EEG, and cognitive side effects of ketamine and methohexital anesthesia with ECT. This comparison was carried out with data from consecutive index ECT treatments that occurred immediately bef ...
Full textLink to itemCite
Journal articleClin Cornerstone · 2003
Featured Publication
Insomnia is a highly prevalent disorder that can lead to substantial impairments in quality of life and functional capacity. This condition occurs significantly more frequently in women than men. An important contributing factor is that insomnia can occur ...
Full textLink to itemCite
Journal articleInternational Journal of Bifurcation and Chaos in Applied Sciences and Engineering · January 1, 2003
We discuss key theoretical and practical issues related to the identification of transitions in dynamical systems in real-time. We focus on the choice of candidate measures and optimization of decision thresholds for candidate measures. To illustrate these ...
Full textCite
Journal articleSleep · September 15, 2002
Featured Publication
STUDY OBJECTIVES: To determine whether the frequency spectrum of the sleep EEG is a physiologic correlate of 1) the degree to which individuals with persistent primary insomnia (PPI) underestimate their sleep time compared with the traditionally scored pol ...
Link to itemCite
Journal articleCNS Spectr · October 2001
Valerian is a medicinal agent deriving from the plant Valeriana officinalis L. We reviewed the available literature on the use of valerian preparations in the treatment of neuropsychiatric disorders. Preclinical studies suggest that valerian has sedative a ...
Full textLink to itemCite
Journal articleJournal of the Royal Statistical Society Series C Applied Statistics · January 1, 2001
Multiple time series of scalp electrical potential activity are generated routinely in electroencephalographic (EEG) studies. Such recordings provide important non-invasive data about brain function in human neuropsychiatric disorders. Analyses of EEG trac ...
Full textCite
Journal articleJ ECT · December 2000
Featured Publication
The optimization of electroconvulsive therapy (ECT) stimulus dosing remains uncertain. Previous work suggests the potential utility of ictal EEG models of seizure adequacy, but such models have never been tested for their ability to improve the clinical do ...
Full textLink to itemCite
Journal articleJ ECT · December 2000
Featured Publication
BACKGROUND: The choice of whether to administer nondominant unilateral (UL) or bilateral (BL) ECT remains controversial. METHODS: A study in which moderately suprathreshold UL nonresponders at treatment 6 were randomized to UL or BL ECT offered the opportu ...
Full textLink to itemCite
Journal articleAm J Psychiatry · June 2000
Featured Publication
OBJECTIVE: The maximum output charge for ECT devices is limited to 576 millicoulombs in the United States, although there are no data ensuring that this limit will allow consistently effective treatments. The authors examined whether this limit has a negat ...
Full textLink to itemCite
Journal articleDepress Anxiety · 2000
Featured Publication
Electroconvulsive therapy (ECT) involves the use of electrical stimulation to elicit a series of generalized tonic-clonic seizures for therapeutic purposes and is the most effective treatment known for major depression. These treatments have significant ne ...
Full textLink to itemCite
Journal articleBrain Topogr · 2000
Featured Publication
To improve our understanding of the physiology of generalized tonic-clonic (GTC) seizures, we have investigated the stationarity and redundancy of 21-electrode EEG data recorded from ten patients during GTC seizures elicited by electroconvulsive therapy (E ...
Full textLink to itemCite
Journal articleClin Neurophysiol · December 1999
Featured Publication
OBJECTIVE: Those who analyze EEG data require quantitative techniques that can be validly applied to time series exhibiting ranges of non-stationary behavior. Our objective is to introduce a new analysis technique based on formal non-stationary time series ...
Full textLink to itemCite
Journal articleJournal of the American Statistical Association · December 1, 1999
We explore and illustrate the use of time series decomposition methods for evaluating and comparing latent structure in nonstationary electroencephalographic (EEG) traces obtained from depressed patients during brain seizures induced as part of electroconv ...
Full textCite
Journal articleJ Clin Psychiatry · October 1999
Featured Publication
BACKGROUND: Depressed individuals effectively treated with selective serotonin reuptake inhibitors (SSRIs) often report persistent insomnia and require adjunctive sleep-promoting therapy. METHOD: Men (N = 40) and women (N = 150) with a mean age of 41.6 yea ...
Full textLink to itemCite
Journal articleJournal of the American Statistical Association · June 1, 1999
We explore and illustrate the use of time series decomposition methods for evaluating and comparing latent structure in nonstationary electroencephalographic (EEG) traces obtained from depressed patients during brain seizures induced as part of electroconv ...
Full textCite
Journal articleJ ECT · March 1999
Featured Publication
Studies on the relationship of electroencephalographic (EEG) data to the therapeutic response to electroconvulsive therapy (ECT) have been carried out since the 1940s, but for many years they did not yield any consistent correlates. Recent studies, however ...
Link to itemCite
Journal articleSleep Med Rev · November 1998
Despite the fact that a large number of women report sleep disturbances associated with peri-menopausal and post-menopausal periods, there is a surprising lack of literature related to this issue. In fact, there has not been enough work in this area to eve ...
Full textLink to itemCite
Journal articleJ ECT · March 1998
Featured Publication
Many patients who receive electroconvulsive therapy (ECT) are benzodiazepine dependent or are anxious and require benzodiazepine drugs. Because these agents may diminish the therapeutic effectiveness of ECT, we explored the dosing, safety, and efficacy of ...
Link to itemCite
Journal articleJ Neuropsychiatry Clin Neurosci · 1998
Featured Publication
Therapeutic effectiveness of electroconvulsive therapy is influenced by the degree to which the stimulus intensity exceeds the seizure threshold. However, the threshold rises variably over the treatment course, confounding maintenance of desired relative s ...
Full textLink to itemCite
Journal articleElectroencephalogr Clin Neurophysiol · December 1997
Featured Publication
Attributes of the electroencephalogram (EEG) recorded during electroconvulsive therapy (ECT) seizures appear promising for decreasing the uncertainty that exists about how to define a therapeutically adequate seizure. In the present report we study whether ...
Full textLink to itemCite
Journal articleJ Neuropsychiatry Clin Neurosci · 1997
Featured Publication
ECT is an effective and rapidly acting treatment for certain major psychiatric disorders, even in patients with neurologic illness. Further, in some cases the neurologic illness itself also responds to ECT. Patients with some types of neurologic illness ma ...
Full textLink to itemCite
Journal articleElectroencephalogr Clin Neurophysiol · August 1996
Featured Publication
Evidence suggests that quantitative dynamical measures of electroencephalogram (EEG) signals are more appropriate for characterizing the differences between states in an individual rather than as absolute indices. One such measure, the largest Lyapunov exp ...
Full textLink to itemCite
Journal articleSleep · June 1996
Featured Publication
Over the past 15 years, there has been considerable debate concerning the extent to which insomnia patients can be classified into diagnostic subtypes. Despite this debate, relatively little research has been conducted to empirically determine whether natu ...
Link to itemCite
Journal articlePsychiatry Res · May 17, 1996
Featured Publication
Recent evidence suggests that attributes of the ictal electroencephalogram (EEG) may be clinically useful for estimating the extent to which the electroconvulsive therapy (ECT) stimulus exceeds the seizure threshold (relative stimulus intensity). Such a to ...
Full textLink to itemCite
Journal articleConvuls Ther · March 1996
Featured Publication
Ictal EEG indices show promise for separating individual ECT seizures on the basis of treatment electrode placement (ELPL), relative stimulus intensity (Dose), and expected therapeutic response. One factor impeding the effective clinical implementation of ...
Link to itemCite
Journal articleConvuls Ther · September 1995
Featured Publication
Reliable monitoring of electroencephalographic (EEG) and electromyographic electroconvulsive therapy (ECT) seizure duration has become important as these assessments have become a routine part of the clinical practice of ECT. In this regard, accurate autom ...
Link to itemCite
Journal articleBiol Psychiatry · June 1, 1995
Featured Publication
To measure the anticonvulsant effects of a course of electroconvulsive therapy (ECT), we used a flexible stimulus dosage titration procedure to estimate seizure threshold at the first and sixth ECT treatments in 62 patients with depression who were undergo ...
Full textLink to itemCite
Journal articleBiol Psychiatry · May 15, 1995
Featured Publication
We measured initial seizure threshold by means of a structured stimulus dosage titration procedure in a clinical sample of 111 depressed patients undergoing brief-pulse, constant-current electroconvulsive therapy (ECT). Initial seizure threshold was approx ...
Full textLink to itemCite
Journal articleJ Clin Neurophysiol · May 1995
Featured Publication
Technology for conducting ambulatory polysomnography (APSG) has been available for more than a decade, but relatively few studies have used this technology to study the sleep of subjects in their usual home sleeping environments. Herein we suggest the usef ...
Link to itemCite
Journal articleJ Neuropsychiatry Clin Neurosci · 1995
Featured Publication
Relative stimulus intensity above seizure threshold has been shown to affect therapeutic outcome with unilateral ECT. The authors sought to explore whether a multivariate ictal EEG model would permit ongoing clinical assessment of this parameter. Twenty-fi ...
Full textLink to itemCite
Journal articleConvuls Ther · June 1994
Featured Publication
From the beginnings of convulsive therapy, the need for some way to assess the therapeutic adequacy of individual treatments has been apparent. Recent work suggests that seizure therapeutic adequacy and adverse effects are dependent on the extent to which ...
Link to itemCite
Journal articleAnnu Rev Med · 1994
Featured Publication
Physicians attempting to treat certain severe mental disorders have recently shown renewed interest in electroconvulsive therapy (ECT). A number of technical innovations have made ECT safer, as well as more effective. These innovations include oxygenation, ...
Full textLink to itemCite
Journal articleBiol Psychiatry · December 1, 1993
Featured Publication
Recent evidence suggests that electroconvulsive therapy (ECT) efficacy depends upon both electrode placement and the degree to which stimulus dosage exceeds seizure threshold (T), and not simply on surpassing a minimum seizure duration as has been assumed. ...
Full textLink to itemCite
Journal articleJ Clin Neurophysiol · January 1992
Featured Publication
Ambulatory polysomnographic (APSG) assessment of sleep disorders is now possible, but the technique of APSG is sufficiently different from in-laboratory PSG that normative data from in-laboratory PSG may not apply to APSG. This paper reviews the technical ...
Link to itemCite
Journal articlePsychiatr Clin North Am · December 1991
Featured Publication
Because induced seizures have such a fundamental influence on both beneficial and adverse effects associated with ECT, it is crucial that they be monitored as effectively as possible. In practice this process involves a combination of both motor and EEG mo ...
Link to itemCite
Journal articleJ Neuropsychiatry Clin Neurosci · 1990
Featured Publication
Most patients with major depression have increased 24-hour urinary free cortisol and cortisol nonsuppression after dexamethasone administration, which are cornerstones of a diagnosis of Cushing's syndrome. Similarly, Cushing's syndrome patients often suffe ...
Full textLink to itemCite